Skip to main content
. 2019 Jun 10;6(4):e581. doi: 10.1212/NXI.0000000000000581

Figure. (A and B) Effect of canakinumab in muscle strength measured in each patient as mean bilateral GF (A) and TMS (B) during the mean study period of 15.8 months (range 5–33 months).

Figure

No significant or clinically meaningful changes were noted in improving strength or stabilizing disease progression. GF = grip force; TMS = total muscle strength.